Zantac Lawsuit


Researching drug company and regulatory malfeasance for over 16 years
Humanist, humorist

Tuesday, March 17, 2009

Big interest in heavy drugs

Source: nature.com

Author: Katharine Sanderson

Pharmaceutical companies are beginning to bet on the idea that simply switching a hydrogen atom with a heavier isotope in a currently approved drug could create a better drug. Encouraged by results from clinical trials, companies are snapping up intellectual-­property rights on many of the modified drugs.

On 16 March, for example, Concert Pharmaceuticals of Lexington, Massachusetts, reported results of a phase I clinical trial for a version of the antidepressant paroxetine, sold as Seroxat by GlaxoSmith­Kline and first marketed under that trade name in 1992. Concert's version swaps out one or more of the hydrogen atoms in the paroxetine structure (see 'Drug modifications') for deuterium, a heavier isotope of hydrogen that contains a proton and a neutron, rather than just a proton. The company was testing this deuterated version for treating hot flushes without the side effect of standard paroxetine in which the liver enzyme CYP2D6 is inactivated. Because this enzyme metabolizes many other drugs, inactivating it means it is hard to take other drugs along with paroxetine.

Full article here





Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman

SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING

No comments:


Please contact me if you would like a guest post considered for publication on my blog.